NCT06138600 - Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

January 31, 2026

Conditions

HIV Infections

Interventions

DRUG

Cabotegravir Injection [Apretude]

White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.

DRUG

Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)

TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.

Trial Locations (1)

2193

Ezintsha, a division of Wits Health Consortium, Johannesburg